Product Spotlight: Adjuvants

Posted on April 09, 2020


Adobe Stock 181494147

Vaccine adjuvants using heterogeneous monophosphoryl Lipid A (MPL) derived from Salmonella minnesota R595 have proven both safe and effective at inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines. With the introduction of Synthetic MPL derivatives and adjuvant systems, Avanti Polar Lipids has revolutionized immunotherapy and vaccine development.

Now, we manufacture multiple synthetic analogs of MPL—all of them contain a single molecular species that are as effective and as safe when it comes to inducing an immune response as their natural product predecessor. PHAD, 3D-PHAD, and 3D(6-acyl)PHAD are all manufactured according to cGMP guidelines and are available in bulk quantities for your clinical trials.

Adjuvant Systems

Are you spending valuable time and resources on adjuvant formulation development in your immunotherapy or vaccine program? Avanti is ready to support your adjuvant formulation development activities with almost 100 years of combined experience in formulation lipids. We offer formulation services for both pre-clinical and clinical development using our own cGMP manufactured lipids. Batches can be scaled anywhere from a few millimeters to >100 liters, to accommodate whatever stage of clinical development you’re in.

We’ll also work together with your packaging group throughout the entire process, ensuring that we’re providing material suitable for aseptic fill/finish in your final dosage form for clinical trial. Avanti can partner with your CMO when you’re ready for commercialization, to provide a seamless transfer of the formulation for scale-up and manufacturing. For more information, visit our Adjuvants Product Page.